Journal of drug targeting · 2012 · 34 citations · 28 references
PharmacyOncologyPharmacologyCancer PharmacologyCutaneous OncologyDrug DeliveryCancer NanomedicineDrug EncapsulationLiposomal FormulationsLiposome-based DeliveryNanocarriers For TherapeuticsNanomedicineAnticancer ActivityLiposomal Delivery SystemsLiposomal NanocarriersLiposome Delivery SystemsLiposomesLocalized Drug DeliveryPhospholipid-based FormulationsSkin Carcinogenesis
PURPOSE: Tamoxifen (TAM) is a non-steroidal estrogen receptor modulator known for its anticancer activity. Apart from marked breast cancer activity, this drug has also shown potential in treating other types of cancers including skin cancers. TAM is reported to be associated with serious side effects primarily due to its systemic distribution. The localized delivery of this drug in this regard would be highly beneficial with respect to safety as well as efficacy. METHODS: In the current studies, an endeavor has been made to investigate the efficacy of topically applied liposome-encapsulated TAM on skin cancer model. The drug was encapsulated in phospholipid-based vesicular systems viz. conventional liposomes and elastic liposomes. Incidence of papillomas and histopathological examination were employed to determine the efficacy of the tested formulations. RESULTS: The results demonstrated carrier-dependent strong inhibition of skin carcinogenesis with encapsulated drug vis-à-vis drug in the solution form. The encouraging findings from the current work construe immense potential of the TAM-loaded liposomal systems in the management of skin cancer.
28
Gregor Cevc, Dieter Gebauer, Juliane Stieber et al. · Biochimica et Biophysica Acta (BBA) - Biomembranes · 1998 · 475 citations
Hanan S. Samaha, Gary J. Kelloff, Vernon E. Steele et al. · PubMed · 1997 · 297 citations
Medicine, Oncology, Pharmacology +17
Deformable liposomes for dermal administration of methotrexate
Michele Trotta, Elena Peira, Maria Eugenia Carlotti et al. · International Journal of Pharmaceutics · 2003 · 280 citations